Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway.

BACKGROUND The development of a novel BRAF inhibitor, vemurafenib, has been associated with impressive tumor regression in patients with BRAF-positive stage IV melanoma. In the phase 3 clinical trials, dermatologic toxic effects associated with vemurafenib were described, namely, the development of eruptive squamous cell carcinomas. Herein, 3 cases are presented that highlight the development of squamous cell carcinomas and other cutaneous sequelae that have not been previously reported and are reminiscent of those observed with administration of the multikinase inhibitor sorafenib tosylate. In addition, the current understanding of the molecular mechanisms underlying these toxic effects is reviewed. OBSERVATIONS The development of keratosis pilaris-like eruptions; seborrheic dermatitis-like rashes; and hyperkeratotic, tender plantar papules reminiscent of those seen in sorafenib-associated hand-foot skin reaction, as well as squamous cell carcinomas, is presented in association with vemurafenib-based treatment of metastatic melanoma. CONCLUSIONS The development of sorafenib-like cutaneous sequelae (squamous cell carcinomas, keratosis pilaris-like eruptions, seborrheic dermatitis-like rashes, and hand-foot skin reaction) associated with vemurafenib administration suggests that BRAF inhibition alone may be sufficient to induce these changes.

[1]  C. Péchoux,et al.  c-myc and c-Ha-ras cellular oncogenes and human papillomaviruses in benign and malignant cutaneous lesions. , 1992, Journal of dermatological science.

[2]  I. Weinstein,et al.  Activated ras genes occur in human actinic keratoses, premalignant precursors to squamous cell carcinomas. , 1995, Archives of dermatology.

[3]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[4]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[5]  Alain Spatz,et al.  Cutaneous side-effects of kinase inhibitors and blocking antibodies. , 2005, The Lancet. Oncology.

[6]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[7]  M. Santoro,et al.  BAY 43-9006 inhibition of oncogenic RET mutants. , 2006, Journal of the National Cancer Institute.

[8]  M. Ratain,et al.  Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis , 2006, British Journal of Cancer.

[9]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[10]  J. Llovet,et al.  Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling , 2008, Molecular Cancer Therapeutics.

[11]  C. Robert,et al.  Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. , 2008, Archives of dermatology.

[12]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[13]  H. Kong,et al.  Array of cutaneous adverse effects associated with sorafenib. , 2009, Journal of the American Academy of Dermatology.

[14]  C. Jaworsky,et al.  The histologic spectrum of epithelial neoplasms induced by sorafenib. , 2009, Journal of the American Academy of Dermatology.

[15]  H. Kong,et al.  Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy , 2009, Clinical Cancer Research.

[16]  Kam Y. J. Zhang,et al.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.

[17]  Jihyun Kim,et al.  Inhibition of mutated BRAF in melanoma. , 2010, The New England journal of medicine.

[18]  F. Goldwasser,et al.  Toxicity of sorafenib: clinical and molecular aspects , 2010, Expert opinion on drug safety.

[19]  M. Belvin,et al.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.

[20]  Chao Zhang,et al.  RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.

[21]  J. Reis-Filho,et al.  Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.

[22]  D. Siegel,et al.  Dermatological findings in 61 mutation‐positive individuals with cardiofaciocutaneous syndrome , 2011, The British journal of dermatology.

[23]  S. Bhambri.  Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib , 2011 .

[24]  Invasive squamous cell carcinoma and sorafenib in a black patient. , 2010, Archives of dermatology.

[25]  A. Eggermont,et al.  Skin Tumors Induced by Sorafenib; Paradoxic RAS–RAF Pathway Activation and Oncogenic Mutations of HRAS, TP53, and TGFBR1 , 2011, Clinical Cancer Research.

[26]  Martin Zenker,et al.  Clinical manifestations of mutations in RAS and related intracellular signal transduction factors , 2011, Current opinion in pediatrics.

[27]  C. Robert,et al.  RAF inhibition and induction of cutaneous squamous cell carcinoma , 2011, Current opinion in oncology.

[28]  Z. Wu,et al.  Meta‐analysis of dermatological toxicities associated with sorafenib , 2011, Clinical and experimental dermatology.

[29]  T. Eberlein,et al.  Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .